PB1884: ENGAGING INNATE IMMUNITY: A PHASE 1 DOSE ESCALATION STUDY TO ASSESS SAFETY AND TOLERABILITY OF AFM28 MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CD123‐POSITIVE ACUTE MYELOID LEUKEMIA (AML)

MLA

Arnan, Montserrat, et al. “Pb1884: Engaging Innate Immunity: A Phase 1 Dose Escalation Study to Assess Safety and Tolerability of Afm28 Monotherapy in Patients with Relapsed/Refractory Cd123‐Positive Acute Myeloid Leukemia (Aml).” HemaSphere, vol. 7, Aug. 2023, pp. 1–2. EBSCOhost, https://doi.org/10.1097/01.HS9.0000974360.24047.92.

APA

Arnan, M., Montesinos, P., de Botton, S., Recher, C., Wunderle, L., Emig, M., Harstrick, A., Pietzko, K., Pinto, S., Ravenstijn, P., & Daver, N. (2023). Pb1884: Engaging Innate Immunity: A Phase 1 Dose Escalation Study to Assess Safety and Tolerability of Afm28 Monotherapy in Patients with Relapsed/Refractory Cd123‐Positive Acute Myeloid Leukemia (Aml). HemaSphere, 7, 1–2. https://doi.org/10.1097/01.HS9.0000974360.24047.92

Chicago

Arnan, Montserrat, Pau Montesinos, Stéphane de Botton, Christian Recher, Lydia Wunderle, Michael Emig, Andreas Harstrick, et al. 2023. “Pb1884: Engaging Innate Immunity: A Phase 1 Dose Escalation Study to Assess Safety and Tolerability of Afm28 Monotherapy in Patients with Relapsed/Refractory Cd123‐Positive Acute Myeloid Leukemia (Aml).” HemaSphere 7 (August): 1–2. doi:10.1097/01.HS9.0000974360.24047.92.